working-with-human-tissues-for-translational-cancer-research

Working with Human Tissues for Translational Cancer Research

Medical research for human benefit is greatly impeded by the necessity for human tissues and subjects. However, upon obtaining consent for human ...

University of Texas MD Anderson Cancer Center

BRAF inhibitor (BRAFi) treatment enhances antitumor immunity, but is associated with increased intratumoral PD-L1 expression. MEK inhibitors (MEKi) may alter T-cell function; however, recent studies demonstrate preserved T-cell infiltrate during treatment with BRAFi/MEKi. These data have important implications for combining BRAFi/MEKi and checkpoint blockade in the treatment of melanoma.

Article	Year
Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 26025561	2015
Raising the bar: optimizing combinations of targeted therapy and immunotherapy. Annals of translational medicine\| PubMed ID: 26605318	2015

Jacob Austin-Breneman

Biography

JoVE Journal Publications

Other Publications